Search results
Results from the WOW.Com Content Network
Lipid-lowering agents, also sometimes referred to as hypolipidemic agents, cholesterol-lowering drugs, or antihyperlipidemic agents are a diverse group of pharmaceuticals that are used to lower the level of lipids and lipoproteins, such as cholesterol, in the blood (hyperlipidemia). The American Heart Association recommends the descriptor ...
From 1996 to 2012, under the trade name Lipitor, atorvastatin became the world's best-selling medication of all time, with more than $125 billion in sales over approximately 14.5 years. [116] and $13 billion a year at its peak, [117] Lipitor alone "provided up to a quarter of Pfizer Inc.'s annual revenue for years." [116]
There is some evidence that appropriate use of statin medications in people with chronic kidney disease who do not require dialysis may reduce mortality and the incidence of major cardiac events by up to 20% and are not that likely to increase the risk of stroke or kidney failure. [16] Asthma. Statins have been identified as having a possible ...
And while 47 million people opt to lower their cholesterol by taking a class of drugs called statins (one of which is the most-prescribed drug in the nation), going this route can be a complicated ...
A few short bursts of exercise throughout the day may reduce heart disease risk by 50%, according to new research. Women specifically showed the most pronounced effects of short bursts of activity ...
In other words, as many as 4 million people in the U.S. who currently take statins for primary prevention — meaning they have not had a cardiovascular event such as a stroke or heart attack ...
Research shows that up to 60% of the weight loss from prescription medications may come from lean body mass. Muscle loss can affect strength and mobility, so eating enough protein to preserve lean ...
The Lancet's editorial position is that the data for Crestor's superiority rely too much on extrapolation from the lipid profile data (surrogate end-points) and too little on hard clinical end-points, which are available for other statins that had been on the market longer. The manufacturer responded by stating that few drugs had been tested so ...